AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease October 3, 2025
Sitryx receives FDA clearance of IND application for SYX-5219 for the treatment of atopic dermatitis October 2, 2025
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate September 30, 2025
Crystalys Therapeutics Launches with $205M Series A Financing to Transform the Treatment of Gout September 30, 2025
Evommune Presents Full Phase 2 Data for Oral MRGPRX2 Inhibitor EVO756 in Chronic Inducible Urticaria During Late-Breaker at EADV 2025 Congress September 19, 2025
